Leerink Partnrs Issues Negative Estimate for Genfit Earnings

Genfit S.A. (NASDAQ:GNFT) – Investment analysts at Leerink Partnrs lowered their FY2024 earnings estimates for shares of Genfit in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings per share of $0.60 for the year, down from their previous estimate of $0.61. The consensus estimate for Genfit’s current full-year earnings is $0.96 per share. Leerink Partnrs also issued estimates for Genfit’s FY2029 earnings at ($0.53) EPS.

Separately, HC Wainwright reiterated a “buy” rating and set a $13.00 target price on shares of Genfit in a research note on Friday, October 11th.

Genfit Stock Performance

Shares of NASDAQ GNFT opened at $3.99 on Thursday. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.74 and a quick ratio of 3.74. The business’s 50 day moving average price is $3.76 and its two-hundred day moving average price is $4.43. Genfit has a twelve month low of $3.35 and a twelve month high of $6.42.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.